Physicochemical Properties
| Molecular Formula | C19H25CLN2S |
| Molecular Weight | 348.93 |
| Exact Mass | 348.143 |
| CAS # | 1094-08-2 |
| Related CAS # | 1094-08-2 (HCl);522-00-9; |
| PubChem CID | 122824 |
| Appearance | White to off-white solid powder |
| Boiling Point | 430.1ºC at 760 mmHg |
| Melting Point | 225 - 228 °C |
| Flash Point | 213.9ºC |
| Vapour Pressure | 1.34E-07mmHg at 25°C |
| LogP | 5.886 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 23 |
| Complexity | 322 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | VXPCQISYVPFYRK-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C19H24N2S.ClH/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21;/h6-13,15H,4-5,14H2,1-3H3;1H |
| Chemical Name | N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine;hydrochloride |
| Synonyms | Ethopropazine Hydrochloride; Pardisol; Dibutil; Parphezein; Profenamine HCl Parfezin; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Enhancement of dissolution of ethopropazine using solid dispersions prepared with phospholipid and/or polyethylene glycol. Drug Dev Ind Pharm. 2001 May;27(5):413-8. [2]. Activity of cholinesterases in human whole blood measured with acetylthiocholine as substrate and ethopropazine as selective inhibitor of plasma butyrylcholinesterase. Arh Hig Rada Toksikol. 2004 Apr;55(1):1-4. |
| Additional Infomation | Profenamine hydrochloride is the monohydrochloride salt of profenamine. An antimuscarinic, it is used for the symptomatic treatment of Parkinson's disease. It has a role as an adrenergic antagonist, a histamine antagonist, an antiparkinson drug and a muscarinic antagonist. It contains a profenamine. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~25 mg/mL (~71.65 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8659 mL | 14.3295 mL | 28.6590 mL | |
| 5 mM | 0.5732 mL | 2.8659 mL | 5.7318 mL | |
| 10 mM | 0.2866 mL | 1.4330 mL | 2.8659 mL |